SEARCH
検索詳細
足立 直子バイオシグナル総合研究センター助教
研究活動情報
■ 論文- At least 10% of proteins constituting the human proteome are subject to S-acylation by a long-chain fatty acid, thioesterified to a Cys thiol side chain. Fatty S-acylation (prototypically, S-palmitoylation) operates across eukaryotic phylogeny and cell type. S-palmitoylation is carried out in mammalian cells by a family of 23-24 dedicated zDHHC palmitoyl transferase enzymes, and mutation of zDHHCs is associated with a number of human pathophysiologies. Activation of the zDHHCs by auto-S-palmitoylation, the transthioesterification of the active site Cys by fatty acyl-CoA, is the necessary first step in zDHHC-mediated protein S-palmitoylation. Most prior in vitro assessments of zDHHC activation have utilized purified zDHHCs, a time- and effort-intensive approach, which removes zDHHCs from their native membrane environment. We describe here a facile assay for zDHHC activation in native membranes. We overexpressed HA-tagged wild-type or mutant zDHHCs in cultured HEK293 cells and prepared a whole membrane fraction, which was incubated with fluorescent palmitoyl CoA (NBD-palmitoyl-CoA) followed by SDS-PAGE, fluorescence imaging and western blotting for HA. We show by mutational analysis that, as assayed, zDHHC auto-S-palmitoylation by NBD-palmitoyl-CoA is limited to the active site Cys. Application of the assay revealed differential effects on zDHHC activation of posttranslational zDHHC modification, and of zDHHC mutations associated with human disease, in particular cancer. Our assay provides a facile means of assessing zDHHC activation and thus of differentiating the effects of zDHHC mutation and post-translational modification on zDHHC activation versus secondary effects on zDHHC functionality resulting from altered zDHHC interaction with substrate palmitoyl-proteins.2025年01月, Journal of lipid research, 100743 - 100743, 英語, 国際誌研究論文(学術雑誌)
- The neurotransmitter serotonin (5-HT) is transported back into serotonergic neurons by the serotonin transporter (SERT). SERT is a main target of antidepressants, and much effort has therefore focused on finding relationships between SERT and depression. However, it is not fully understood how SERT is regulated at the cellular level. Here, we report post-translational regulation of SERT by S-palmitoylation, in which palmitate is covalently attached to cysteine residues of proteins. Using AD293 cells (a human embryonic kidney 293-derived cell line with improved cell adherence) transiently transfected with FLAG-tagged human SERT, we observed S-palmitoylation of immature SERT containing high-mannose type N-glycans or no N-glycan, which is presumed to be localized in the early secretory pathway, such as the endoplasmic reticulum. Mutational analysis by alanine substitutions shows that S-palmitoylation of immature SERT occurs at least at Cys-147 and Cys-155, juxtamembrane cysteine residues within the first intracellular loop. Furthermore, mutation of Cys-147 reduced cellular uptake of a fluorescent SERT substrate that mimics 5-HT without decreasing SERT on the cell surface. On the other hand, combined mutation of Cys-147 and Cys-155 inhibited SERT surface expression and reduced the uptake of the 5-HT mimic. Thus, S-palmitoylation of Cys-147 and Cys-155 is important for both the cell surface expression and 5-HT uptake capacity of SERT. Given the importance of S-palmitoylation in brain homeostasis, further investigation of SERT S-palmitoylation could provide new insights into the treatment of depression.2023年06月, Biochemical and biophysical research communications, 662, 58 - 65, 英語, 国際誌研究論文(学術雑誌)
- Palmitoylation is a lipid modification involving the attachment of palmitic acid to a cysteine residue, thereby affecting protein function. We investigated the effect of palmitoylation of tyrosinase, the rate-limiting enzyme in melanin synthesis, using a human three-dimensional skin model system and melanocyte culture. The palmitoylation inhibitor, 2-bromopalmitate, increased melanin content and tyrosinase protein levels in melanogenic cells by suppressing tyrosinase degradation. The palmitoylation site was Cysteine500 in the C-terminal cytoplasmic tail of tyrosinase. The nonpalmitoylatable mutant, tyrosinase (C500A), was slowly degraded and less ubiquitinated than wild-type tyrosinase. Screening for the Asp-His-His-Cys (DHHC) family of proteins for tyrosinase palmitoylation suggested that DHHC2, 3, 7, and 15 are involved in tyrosinase palmitoylation. Knockdown of DHHC2, 3, or 15 increased tyrosinase protein levels and melanin content. Determination of their subcellular localization in primary melanocytes revealed that DHHC2, 3, and 15 were localized in the endoplasmic reticulum, Golgi apparatus, and/or melanosomes, whereas only DHHC2 was localized in the melanosomes. Immunoprecipitation showed that DHHC2 and DHHC3 predominantly bind to mature and immature tyrosinase, respectively. Taken together, tyrosinase palmitoylation at Cysteine500 by DHHC2, 3, and/or 15, especially DHHC2 in trans-Golgi apparatus and melanosomes and DHHC3 in the endoplasmic reticulum and cis-Golgi apparatus, regulate melanogenesis by modulating tyrosinase protein levels.2022年09月, The Journal of investigative dermatology, 143(2) (2), 317 - 327, 英語, 国際誌研究論文(学術雑誌)
- The β2-adrenergic receptor (β2AR), a prototypic G-protein-coupled receptor (GPCR), is a powerful driver of bronchorelaxation, but the effectiveness of β-agonist drugs in asthma is limited by desensitization and tachyphylaxis. We find that during activation, the β2AR is modified by S-nitrosylation, which is essential for both classic desensitization by PKA as well as desensitization of NO-based signaling that mediates bronchorelaxation. Strikingly, S-nitrosylation alone can drive β2AR internalization in the absence of traditional agonist. Mutant β2AR refractory to S-nitrosylation (Cys265Ser) exhibits reduced desensitization and internalization, thereby amplifying NO-based signaling, and mice with Cys265Ser mutation are resistant to bronchoconstriction, inflammation, and the development of asthma. S-nitrosylation is thus a central mechanism in β2AR signaling that may be operative widely among GPCRs and targeted for therapeutic gain.2022年08月, Molecular cell, 82(16) (16), 3089 - 3102, 英語, 国際誌研究論文(学術雑誌)
- (公社)日本生化学会, 2020年09月, 日本生化学会大会プログラム・講演要旨集, 93回, [1Z09 - 161)], 日本語67kDaラミニンレセプターはビタミンEとの結合によりパルミトイル化修飾を受ける
- 日本組織細胞化学会, 2019年09月, 日本組織細胞化学会総会・学術集会講演プログラム・予稿集, 60回, 85 - 85, 日本語Cysteine String Protein alpha(CSPα)Ser34特異的リン酸化抗体の作製と機能解析
- Spinocerebellar ataxia type 14 (SCA14) is an autosomal dominant neurodegenerative disorder characterized by cerebellar ataxia with myoclonus, dystonia, spasticity, and rigidity. Although missense mutations and a deletion mutation have been found in the protein kinase C gamma (PRKCG) gene encoding protein kinase C γ (PKCγ) in SCA14 families, a nonsense mutation has not been reported. The patho-mechanisms underlying SCA14 remain poorly understood. However, gain-of-function mechanisms and loss-of-function mechanisms, but not dominant negative mechanisms, were reported the patho-mechanism of SCA14. We identified the c.226C>T mutation of PRKCG, which caused the p.R76X in PKCγ by whole-exome sequencing in patients presenting cerebellar atrophy with cognitive and hearing impairment. To investigate the patho-mechanism of our case, we studied aggregation formation, cell death, and PKC inhibitory effect by confocal microscopy, western blotting with cleaved caspase 3, and pSer PKC motif antibodies, respectively. PKCγ(R76X)-GFP have aggregations the same as wild-type (WT) PKCγ-GFP. The PKCγ(R76X)-GFP inhibited PKC phosphorylation activity more than GFP alone. It also induced more apoptosis in COS7 and SH-SY5Y cells compared to WT-PKCγ-GFP and GFP. We first reported SCA14 patients with p.R76X in PKCγ who have cerebellar atrophy with cognitive and hearing impairment. Our results suggest that a dominant negative mechanism due to truncated peptides produced by p.R76X may be at least partially responsible for the cerebellar atrophy.2019年07月, Molecular and cellular neurosciences, 98, 46 - 53, 英語, 国際誌[査読有り]研究論文(学術雑誌)
- With few reported exceptions, G protein-coupled receptors (GPCRs) are modified by Cys palmitoylation (S-palmitoylation). In multiple GPCRs, S-palmitoylation targets a canonical site within the C-terminal cytoplasmic tail adjacent to the C terminus of the seventh transmembrane domain, but modification of additional sites is exemplified by the β-adrenergic receptors (βARs). The β1AR is S-palmitoylated at a second, more distal site within the C-terminal tail, and the β2AR is modified at a second site within the third intracellular loop, neither of which is conserved in other βAR isoforms. The functional roles of S-palmitoylation of disparate sites are incompletely characterized for any GPCR family. Here, we describe S-palmitoylation of the β3AR. We compared mouse and human β3ARs and found that both were S-palmitoylated at the canonical site within the C-terminal tail, Cys-358 and Cys-361/363 in mouse and human β3ARs, respectively. Surprisingly, the human β3AR was S-palmitoylated at two additional sites, Cys-153 and Cys-292 within the second and third intracellular loops, respectively. Cys-153 is apparently unique to the human β3AR, and Cys-292 is conserved primarily in primates. Mutational substitution of C-tail Cys in human but not mouse β3ARs resulted in diminished ligand-induced cAMP production. Substitution of Cys-153, Cys-292, or Cys-361/363 within the human β3AR diminished membrane-receptor abundance, but only Cys-361/363 substitution diminished membrane-receptor half-life. Thus, S-palmitoylation of different sites differentially regulates the human β3AR, and differential S-palmitoylation distinguishes human and rodent β3ARs, potentially contributing to species-specific differences in the clinical efficacy of β3AR-directed pharmacological approaches to disease.2019年02月, J Biol Chem, 294(7) (7), 2569 - 2578, 英語, 国際誌[査読有り]研究論文(学術雑誌)
- 2018年09月, J Biol Chem, 293(38) (38), 14758 - 14774, 英語, 国際誌[査読有り]研究論文(学術雑誌)
- Japanese Pharmacological Society, 2018年05月, Journal of Pharmacological Sciences, 137(1) (1), 20 - 29, 英語, 国内誌[査読有り]研究論文(学術雑誌)
- Society for Neuroscience, 2018年01月, J Neurosci, 38(2) (2), 278 - 290, 英語, 国際誌[査読有り]研究論文(学術雑誌)
- 2017年03月, GENES TO CELLS, 22(3) (3), 310 - 327, 英語, 国際誌[査読有り]研究論文(学術雑誌)
- 2016年09月, J Biol Chem, 291(38) (38), 20232 - 20246, 英語, 国際誌[査読有り]研究論文(学術雑誌)
- 2015年01月, Hum Mol Genet, 24(2) (2), 525 - 539, 英語, 国際誌[査読有り]研究論文(学術雑誌)
- (一社)日本神経学会, 2014年12月, 臨床神経学, 54(Suppl.) (Suppl.), S242 - S242, 日本語PKCγKOパーキンソン症候群モデル βPIXリン酸化のドパミン遊離での役割
- 2014年07月, J Neurosci, 34(28) (28), 9268 - 9280, 英語, 国際誌[査読有り]研究論文(学術雑誌)
- 2014年04月, FRONTIERS IN PHYSIOLOGY, 5, 126 - 126, 英語, 国際誌[査読有り]研究論文(学術雑誌)
- 2013年10月, Biochemical and biophysical research communications, 440(1) (1), 25 - 30, 英語[査読有り]研究論文(学術雑誌)
- (公社)日本薬理学会, 2012年10月, 日本薬理学雑誌, 140(4) (4), 1P - 1P, 日本語黒質線条体系におけるPKCγの基質の解析
- 2011年07月, Journal of pharmacological sciences, 116(3) (3), 239 - 247, 英語[査読有り]研究論文(学術雑誌)
- (公社)日本薬理学会, 2011年03月, 日本薬理学雑誌, 137(3) (3), 22P - 22P, 日本語PKCγノックアウトは黒質線条体ドパミン神経系の異常をもたらす
- (一社)兵庫県医師会, 2011年03月, 兵庫県医師会医学雑誌, 53(2) (2), 63 - 63, 日本語PKCγノックアウトマウスを用いたパーキンソン症候群モデルの作製
- 2011年, J. Pharmacol. Sci., 116(3) (3), 239 - 247, 英語[査読有り]研究論文(学術雑誌)
- 2010年10月, JOURNAL OF BIOLOGICAL CHEMISTRY, 285(43) (43), 33252 - 33264, 英語[査読有り]研究論文(学術雑誌)
- 2010年10月, Journal of pharmacological sciences, 114(2) (2), 206 - 216, 英語[査読有り]研究論文(学術雑誌)
- 2010年05月, GENES TO CELLS, 15(5) (5), 425 - 437, 英語[査読有り]研究論文(学術雑誌)
- :Several missense mutations in the protein kinase Cγ (γPKC) gene have been found to cause spinocerebellar ataxia type 14 (SCA14), an autosomal dominant neurodegenerative disease. We previously demonstrated that the mutant γPKC found in SCA14 is susceptible to aggregation that induces apoptotic cell death. Congo red is widely used as a histological dye for amyloid detection. Recent evidence has revealed that Congo red has the property to inhibit amyloid oligomers and fibril formation of misfolded proteins. In the present study, we examine whether Congo red inhibits aggregate formation and cytotoxicity of mutant γPKC. Congo red likely inhibits aggregate formation of mutant γPKC – green fluorescent protein (GFP) without affecting its expression level in SH-SY5Y cells. Congo red counteracts the insolubilization of recombinant mutant γPKC, suggesting that the dye inhibits aggregation of mutant γPKC by a direct mechanism. Congo red also inhibits aggregation and oligomerization of mutant γPKC-GFP in primary cultured cerebellar Purkinje cells. Moreover, the dye reverses the improper development of dendrites and inhibits apoptotic cell death in Purkinje cells that express mutant2010年, J. Pharmacol. Sci., 114(2) (2), 33252 - 33264[査読有り]研究論文(学術雑誌)
- :Several missense mutations in the protein kinase Cγ (γPKC) gene have been found to cause spinocerebellar ataxia type 14 (SCA14), an autosomal dominant neurodegenerative disease. We previously demonstrated that the mutant γPKC found in SCA14 is susceptible to aggregation, which induces apoptotic cell death. The disaccharide trehalose has been reported to inhibit aggregate formation and to alleviate symptoms in cellular and animal models of Huntington disease, Alzheimer disease, and prion disease. Here, we show that trehalose can be incorporated into SH-SY5Y cells and reduces the aggregation of mutant γPKC-GFP, thereby inhibiting apoptotic cell death in SH-SY5Y cells and primary cultured Purkinje cells (PCs). Trehalose acts by directly stabilizing the conformation of mutant γPKC without affecting protein turnover. Trehalose was also found to alleviate the improper development of dendrites in PCs expressing mutant γPKC-GFP without aggregates but not in PCs with aggregates. In PCs without aggregates, trehalose improves the mobility and translocation of mutant γPKC-GFP, probably by inhibiting oligomerization and thereby alleviating the improper development of dendrites. These re2010年, J Biol. Chem., 285(43) (43), 33252 - 33264[査読有り]研究論文(学術雑誌)
- Blackwell Publishing Ltd, 2010年, Genes to Cells, 15(5) (5), 425 - 438, 英語[査読有り]研究論文(学術雑誌)
- 2009年02月, NEUROBIOLOGY OF DISEASE, 33(2) (2), 260 - 273, 英語[査読有り]研究論文(学術雑誌)
- :Missense mutations in protein kinase Cgamma (gammaPKC) gene have been found in spinocerebellar ataxia type 14 (SCA14), an autosomal dominant neurodegenerative disease. We previously demonstrated that mutant gammaPKC found in SCA14 is susceptible to aggregation and induces apoptosis in cultured cell lines. In the present study, we investigated whether mutant gammaPKC formed aggregates and how mutant gammaPKC affects the morphology and survival of cerebellar Purkinje cells (PCs), which are degenerated in SCA14 patients. Adenovirus-transfected primary cultured PCs expressing mutant gammaPKC-GFP also had aggregates and underwent apoptosis. Long-term time-lapse observation revealed that PCs have a potential to eliminate aggregates of mutant gammaPKC-GFP. Mutant gammaPKC-GFP disturbed the development of PC dendrites and reduced synapse formation, regardless of the presence or absence of its aggregates. In PCs without aggregates, mutant gammaPKC-GFP formed soluble oligomers, resulting in reduced mobility and attenuated translocation of mutant gammaPKC-GFP upon stimulation. These molecular properties of mutant gammaPKC might affect the dendritic morphology in PCs, and be involved in the p2009年, Neurobiol. Dis., 33(2) (2), 260 - 273[査読有り]研究論文(学術雑誌)
- 2008年12月, EUROPEAN JOURNAL OF NEUROSCIENCE, 28(12) (12), 2409 - 2422, 英語[査読有り]研究論文(学術雑誌)
- 2008年08月, FEBS JOURNAL, 275(16) (16), 3988 - 3994, 英語[査読有り]
- 2008年07月, JOURNAL OF BIOLOGICAL CHEMISTRY, 283(28) (28), 19854 - 19863, 英語[査読有り]研究論文(学術雑誌)
- 2007年12月, EUROPEAN JOURNAL OF NEUROSCIENCE, 26(11) (11), 3126 - 3140, 英語[査読有り]研究論文(学術雑誌)
- 2006年12月, NEUROCHEMISTRY INTERNATIONAL, 49(7) (7), 669 - 675, 英語[査読有り]研究論文(学術雑誌)
- (一社)日本神経学会, 2006年12月, 臨床神経学, 46(12) (12), 1111 - 1111, 日本語SCA14の発症機構の検討 ユビキチン-プロテアソーム系との関連
- (一社)日本神経学会, 2005年12月, 臨床神経学, 45(12) (12), 1077 - 1077, 日本語遺伝性脊髄小脳失調症14型(SCA14)で見いだされた変異γPKCの性質
- 2005年10月, MOLECULAR BRAIN RESEARCH, 139(2) (2), 288 - 299, 英語[査読有り]研究論文(学術雑誌)
- 2005年08月, JOURNAL OF BIOLOGICAL CHEMISTRY, 280(32) (32), 29096 - 29106, 英語[査読有り]研究論文(学術雑誌)
- 2005年04月, GENES TO CELLS, 10(4) (4), 311 - 319, 英語[査読有り]研究論文(学術雑誌)
- 日本組織細胞化学会, 2019年09月, 日本組織細胞化学会総会・学術集会講演プログラム・予稿集, 60回, 70 - 70, 日本語脊髄小脳変性症14型モデルマウスを用いた薬物治療法の探索
- 2014年, JOURNAL OF PHARMACOLOGICAL SCIENCES, 124, 207P - 207P, 英語A protein kinase C-gamma knockout Parkinsonian model: Involvement of Pak-Interacting Exchange Factor-beta研究発表ペーパー・要旨(国際会議)
- 2013年, JOURNAL OF PHARMACOLOGICAL SCIENCES, 121, 122P - 122P, 英語Analysis of PKCY substrates in nigro-striatum system:The role of beta PIX phosphorylation in the dopamine release研究発表ペーパー・要旨(国際会議)
- 2007年06月05日, 脂質生化学研究, 49, 15 - 15, 日本語DG-PKCシグナル系の可視化とその異常による疾患
- 2007年, NEUROSCIENCE RESEARCH, 58, S118 - S118, 英語Effects of mutant gamma PKC found in SCA14 on the nature of primary cultured Purkinje cells研究発表ペーパー・要旨(国際会議)
- 2007年, JOURNAL OF PHARMACOLOGICAL SCIENCES, 103, 139P - 139P, 英語Mutant gamma PKC found in SCA14 forms cytotoxic aggregates in a microtubule-dependent manner.研究発表ペーパー・要旨(国際会議)
- (公社)日本薬理学会, 2006年08月, 日本薬理学雑誌, 128(2) (2), 20P - 20P, 日本語遺伝性脊髄小脳失調症を引き起こすγPKC変異の新規同定と同定された変異γPKCの性質
- 2006年, NEUROSCIENCE RESEARCH, 55, S202 - S202, 英語Ubiquitin proteasome system was impaired by the aggregate formation of mutant gamma PKC found in SCA14研究発表ペーパー・要旨(国際会議)
- 2006年, JOURNAL OF PHARMACOLOGICAL SCIENCES, 100, 240P - 240P, 英語Involvement of ubiquitin-proteasome system in the cytotoxic effect of mutant protein kinase C gamma found in spinocerebellar ataxia type 14研究発表ペーパー・要旨(国際会議)
- 2005年, JOURNAL OF PHARMACOLOGICAL SCIENCES, 97, 72P - 72P, 英語Protein kinase C gamma (gamma PKC) mutants found in spinocerebellar ataxia (SCA) preferably aggregate in the cytoplasm研究発表ペーパー・要旨(国際会議)
- Conference on Responses to DNA Damage: from Molecule to Disease, 2016年04月, 英語, Egmond aan Zee, The Netherlands, 国際会議Dynamics of chromatin structure regulating nucleotide excision repairポスター発表
- 第38回日本分子生物学会年会・第88回日本生化学会大会合同大会(BMB2015), 2015年12月, 日本語, 日本分子生物学会, 神戸, 国内会議ヌクレオチド除去修復を制御するクロマチン構造動態の解析ポスター発表
- 第38回日本分子生物学会年会・第88回日本生化学会大会合同大会(BMB2015), 2015年12月, 日本語, 日本分子生物学会, 神戸, 国内会議ヌクレオチド除去修復を制御するクロマチン構造動態の解析ポスター発表
- 第37回日本神経科学大会, 2014年09月, 日本語, 日本神経科学会, 横浜, 国内会議PKC KO Parkinsonian syndrome model:The role of PIX phosphorylation at Ser340 and Ser583 in dopamine release.ポスター発表
- Society for Neuroscience 2014, 2014年09月, 英語, Society for Neuroscience, Washington D.C., USA, 国際会議Analysis of PKC substrates in nigro-striatum system:The role of bPIX phosphorylation for dopamine release.口頭発表(一般)
- 第55回日本神経学会学術大会, 2014年05月, 日本語, 日本神経学会, 福岡, 国内会議PKCノックアウトパーキンソン症候群モデル:bPIXリン酸化のドパミン遊離での役割ポスター発表
- ICHC2012, 2012年08月, 英語, 国際組織細胞化学会, 京都, 国際会議Involvment of PKCgamma in neurodegenerative diseaseシンポジウム・ワークショップパネル(公募)
- 第121回日本薬理学会近畿部会, 2012年03月, 日本語, 日本薬理学会, 徳島, 国内会議黒質線条体系におけるPKCgammaの基質の解析口頭発表(一般)
- 日本学術振興会, 科学研究費助成事業, 基盤研究(B), 神戸大学, 2024年04月01日 - 2027年03月31日活性酸素産生酵素NOX3の発現制御機序解明による後天性及び片側性難聴の治療法開発
- 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2022年04月01日 - 2025年03月31日一酸化窒素によるS-パルミトイル化修飾酵素抑制機構の解明
- 日本学術振興会, 科学研究費助成事業, 基盤研究(B), 神戸大学, 2021年04月01日 - 2024年03月31日Nox3由来ROSによる難聴(加齢、騒音、薬剤、突発性)の発症機序解明とその先へ1. 自ら開発したNADPH oxidase 3 (Nox3) 発現細胞が赤色蛍光蛋白 tdTomato で標識される(Nox3-CreKI;tdTomato+/+)マウスを用い、耳石形成に必須のNox3由来活性酸素(ROS)発生源細胞として、内リンパ嚢・内リンパ管の管腔に面した上皮細胞を特定した。更に、Nox3が一次聴覚感受器官である蝸牛コルチ器に発現することを発見、Nox3発現細胞として、内・外有毛細胞とその周囲に存在し有毛細胞を機能・構造的に支える種々の支持細胞(内・外指節細胞、外柱細胞、クラウディウス細胞)を特定した。 2. 加えて、上記の蝸牛におけるNox3発現(tdTomato陽性)細胞数が、聴毒性で有名な抗癌剤であるシスプラチンの投与および加齢や騒音不可により上昇する事を発見した。特に、Nox3が発現誘導された外有毛細胞は、アポトーシスに陥ることを明らかにした。 3.自ら開発したNox3-knockout (KO)マウスを用いて、シスプラチン誘発感音難聴、加齢性感音難聴、騒音性感音難聴において、Nox3-KOが聴覚温存に働くことを明らかにした。 4.上記3種の主要後天性感音難聴の中で、シスプラチン誘発感音難聴と加齢性感音難聴においてNox3の関与が非常に高く、騒音性感音難聴ではやや低いが有意に関与することを明らかにした。
上記の結果は、Nox3の蝸牛コルチ器(特に、外有毛細胞細胞)での発現抑制が、後天性感音難聴の治療法開発の標的になる事を強く示唆している。 - 科学研究費補助金/基盤研究(B), 2017年04月 - 2020年03月競争的資金
- 学術研究助成基金助成金/基盤研究(C), 2017年04月 - 2020年03月, 研究代表者競争的資金
- 学術研究助成基金助成金/国際共同研究加速基金(国際共同研究強化), 2017年04月 - 2020年03月, 研究代表者競争的資金
- 学術研究助成基金助成金/若手研究(B), 2015年04月 - 2017年03月, 研究代表者競争的資金
- 科学研究費一部基金/基盤研究(B)特設, 2013年04月 - 2016年03月競争的資金
- 科学研究費補助金/若手研究(B), 2012年04月 - 2014年03月, 研究代表者競争的資金
- 科学研究費補助金/若手研究(スタートアップ), 2011年, 研究代表者競争的資金